Alnylam Pharmace. buy Biotechhunter
Summary
This prediction ended on 31.07.20 with a price of €125.52. With a performance of -9.70%, the BUY prediction by Biotechhunter finished with a loss. Biotechhunter has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Alnylam Pharmace. | 0.749% | 0.749% | 38.074% | 52.373% |
| iShares Core DAX® | 0.444% | 3.030% | 12.677% | 49.790% |
| iShares Nasdaq 100 | 3.819% | 4.073% | 33.152% | 88.253% |
| iShares Nikkei 225® | 1.148% | 6.904% | 45.488% | 61.922% |
| iShares S&P 500 | 2.371% | 2.677% | 25.689% | 63.539% |
Comments by Biotechhunter for this prediction
In the thread Alnylam Pharmace. diskutieren
In the thread Trading Alnylam Pharmace.


